Trichostatin A (Synonyms: TSA)

Name: Trichostatin A
Brand: MedChemExpress
SKU: HY-15144
Rating: 5.0 (192 reviews)

Cat. No.: HY-15144 Purity: 99.58%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC.

For research use only. We do not sell to patients.

CAS No. : 58880-19-6

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
2 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 192 publication(s) in Google Scholar

Other Forms of Trichostatin A:

(S)-Trichostatin A Get quote

176 Publications Citing Use of MCE Trichostatin A

RT-PCR

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 18;16(1):1736. [Abstract]; Trichostatin A (TSA) (0.5 µM, 12 h) rescues the let-7d-5p overexpression-induced decrease in E2F1 acetylation and restores the expression of target proteins GLUT1, PFKP, and HK2 in pulmonary fibroblasts.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2413121. [Abstract]; Trichostatin A (TSA) (1 µM, 6 h) increases the lactylation modification of METTL3 in HEK293T cells transfected with the indicated constructs.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan 31:e2408845. [Abstract]; Trichostatin A (TSA) (0.1 µM, 24 h) significantly reduces the expression of FSP1 in CRC cells.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 26:e2405332. [Abstract]; Trichostatin A (TSA) (500 nM, 12 h) significantly enhances SNORA28-mediated upregulation of LIFR mRNA and protein levels in CRC cells with stable SNORA28 overexpression.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Cell Discov. 2024 Sep 17;10(1):96. [Abstract]; Trichostatin A (TSA) (10 μM, 16 h) increases SNRNP200 protein levels in BT-549 cells.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]; A485 (10 μM; 24 h) leads to the downregulation of H3K9bhb and CPS1 in BHB-treated CD8⁺ T_M cells; however, the use of 3-TYP (10 μM; 24 h) or Trichostatin A (TSA; 5 nM; 24 h) result in the increase of H3K9bhb and CPS1.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2023 Nov;30(11):2382-2392. [Abstract]; Trichostatin A (TSA) (0.2 μM, 4 h) increases RACK1 acetylation levels in OVCAR3 and SKOV3 cells when combined with Nicotinamide (NAM) (HY-B0150) (10 mM, 4 h).

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Dec;10(35):e2300698. [Abstract]; Trichostatin A (TSA) (2.5-10 µM, 24 h) reduces the level of AML1‐ETO protein in Kasumi-1 cells.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Cancer Res. 2021 Apr 1;81(7):1813-1826. [Abstract]; Trichostatin A (TSA) (1 μM, 48 h) increases MICA/B mRNA levels in SCLC cell lines H510 and H69.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Sep 20;12(1):5548. [Abstract]; Trichostatin A (TSA) (3 μM, 12 h) increases histone isonicotinylation levels in HepG2 cells.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Feb;12(2):838-852.; Trichostatin A (TSA) (1 μM, 12 h) significantly increases Parkin acetylation levels in HEK293 cells.HEK293 cells were transiently transfected with Flag-Parkin and then treated with 1 μmol/L TSA for 12 h. Cells were lysed and subjected to FLAG immunoprecipitation followed by immunoblotting for acetyl-lysine.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Theranostics. 2019 Apr 13;9(9):2424-2438. [Abstract]; Trichostatin A (TSA) (5 μM, 16 h) increases endogenous FH acetylation in cell.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Kidney Int. 2017 Sep;92(3):669-679. [Abstract]; PPARγ lysine 240 and 265 are essential for PPARγ acetylation-associated Klotho derepression. Cellular PPARγ acetylation assay. Human embryonic kidney 293 (HEK293) or human proximal tubular epithelial cells (HK2) cells are treated with trichostatin A (TSA) (100 ng/mL) for 4 hours then subjected to immunoprecipitation with anti-PPARγ antibody. Acetylated PPARγ is detected with a pan anti-acetyl-lysine (ac-K) antibody by Western blotting (WB). The cell lysates are also assayed for total PPARg, Klot

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Kidney Int. 2017 Sep;92(3):669-679. [Abstract]; Trichostatin A (TSA) (100 ng/mL, 4 h) enhances the binding of PPARγ and acetylated histone 3 (H3) to PPRE1 in HK2 cells, but does not increase binding to PPRE2 or to promoter regions lacking PPRE (PPREn).

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):9967-76. [Abstract]; SDL screens for TDP1 and validation pipeline. Acetylation levels after treatment with TSA in RMS (RH30) cells.

: Trichostatin A purchased from MedChemExpress. Usage Cited in: Dr. Wang from Chinese Academy of Sciences.; Trichostatin A (TSA) (0.25-0.75 μM, 16 h) significantly elevates the total levels of histone acetylation markers in a dose-dependent manner.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

View All Isoforms

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC^[1].

IC₅₀ & Target^[1]

HDAC

1.8 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.18 μM Compound: TSA	Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A20	IC₅₀	0.002 μM Compound: TSA	In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells In vitro for anti-HDAC1 (Histone deacetylase 1) activity in mouse A20 cells	[PMID: 11960489]
A2058	IC₅₀	0.43 μM Compound: 4; TSA	Cytotoxicity against human A2058 cells assessed as reduction in cell viability Cytotoxicity against human A2058 cells assessed as reduction in cell viability	[PMID: 32005414]
A2780	IC₅₀	0.22 μM Compound: TSA	Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.25 μM Compound: TSA	Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.29 μM Compound: TSA	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.43 μM Compound: TSA	Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A549	GI₅₀	80 nM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 30004697]
A549	IC₅₀	0.05 μM Compound: TSA	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
A549	IC₅₀	0.05 μM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A549	IC₅₀	0.05 μM Compound: Trichostatin A	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
A549	IC₅₀	0.08 μM Compound: TSA	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 18247554]
A549	IC₅₀	0.08 μM Compound: TSA (1)	Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay	[PMID: 14667227]
A549	IC₅₀	0.16 μM Compound: TSA	Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
A549	IC₅₀	1.31 μM Compound: 4; TSA	Cytotoxicity against human A549 cells assessed as reduction in cell viability Cytotoxicity against human A549 cells assessed as reduction in cell viability	[PMID: 32005414]
A549	IC₅₀	20 nM Compound: TSA	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 30245394]
A549	IC₅₀	4.5 μM Compound: TSA	Inhibitory concentration against lung A549 cell line Inhibitory concentration against lung A549 cell line	[PMID: 12593661]
A549	IC₅₀	80 nM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
BE(2)-C	IC₅₀	0.05 μM Compound: 1, TSA, trichostatin A	Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay	[PMID: 22932316]
BGC-823	IC₅₀	0.07 μM Compound: TSA	Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
BGC-823	IC₅₀	0.08 μM Compound: TSA	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
BGC-823	IC₅₀	0.08 μM Compound: Trichostatin A	Cytotoxicity against human BGC823 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
BT-474	IC₅₀	33.3 nM Compound: 8; TSA	Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition by SRB assay	[PMID: 34826681]
BXPC-3	GI₅₀	100 nM Compound: TSA	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 30004697]
Bel-7402	IC₅₀	0.1 μM Compound: TSA	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
C180-13S	IC₅₀	0.06 μM Compound: 1a	Cytotoxicity of compound against normal human ovarian C18013S cell line Cytotoxicity of compound against normal human ovarian C18013S cell line	[PMID: 15163181]
Cancer cell lines	EC₅₀	1 μM Compound: 1 (trichostatin A)	Concentration of compound required for acetylation of histone-4 in human T24 cancer cells Concentration of compound required for acetylation of histone-4 in human T24 cancer cells	[PMID: 11597413]
DMS-53	IC₅₀	25 nM Compound: Trichostatin A	Cytostatic activity against human DMS53 cells assessed as inhibition of cell proliferation after 2 days by MTT assay Cytostatic activity against human DMS53 cells assessed as inhibition of cell proliferation after 2 days by MTT assay	[PMID: 21504214]
DO4	IC₅₀	0.09 μM Compound: 1a	Cytotoxicity of compound against normal human melanoma DO4 cell line Cytotoxicity of compound against normal human melanoma DO4 cell line	[PMID: 15163181]
DU-145	IC₅₀	0.06 μM Compound: 1a	Cytotoxicity of compound against normal human prostate DU145 cell line Cytotoxicity of compound against normal human prostate DU145 cell line	[PMID: 15163181]
DU-145	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
DU-145	IC₅₀	0.2 μM Compound: TSA	Inhibitory concentration required to reduce DU145 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce DU145 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
DU-145	IC₅₀	3.5 μM Compound: TSA	Inhibitory concentration against prostate DU145 cell line Inhibitory concentration against prostate DU145 cell line	[PMID: 12593661]
Erythrocyte	IC₅₀	0.2 μM Compound: TSA	Cytotoxicity against erythrocytes (unknown origin) Cytotoxicity against erythrocytes (unknown origin)	[PMID: 24904967]
Fibroblast	IC₅₀	0.2 μM Compound: TSA	Toxicity in neonatal foreskin fibroblasts Toxicity in neonatal foreskin fibroblasts	[PMID: 18212103]
Fibroblast	IC₅₀	0.2 μM Compound: TSA	Growth inhibition of human neonatal foreskin fibroblasts cells Growth inhibition of human neonatal foreskin fibroblasts cells	[PMID: 18247554]
Friend leukemia cell line	IC₅₀	0.04 μM Compound: 2	Tested in vivo for the inhibition of proliferation of friend leukemic cells Tested in vivo for the inhibition of proliferation of friend leukemic cells	[PMID: 12109913]
Friend leukemia cell line	IC₅₀	0.04 μM Compound: 2 - TSA	Inhibitory concentration against friend cells proliferation Inhibitory concentration against friend cells proliferation	[PMID: 14613312]
HCT-116	EC₅₀	1 μM Compound: 1 (trichostatin A)	In vitro antiproliferative activity against human colon cancer HCT 116 cells determined by MMT assay In vitro antiproliferative activity against human colon cancer HCT 116 cells determined by MMT assay	[PMID: 11597413]
HCT-116	EC₅₀	1 μM Compound: 2 - TSA	Inhibitory concentration against human colon cancer HCT116 cell proliferation Inhibitory concentration against human colon cancer HCT116 cell proliferation	[PMID: 14613312]
HCT-116	GI₅₀	35 nM Compound: TSA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 30004697]
HCT-116	GI₅₀	35 nM Compound: TSA	Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
HCT-116	IC₅₀	0.0013 μM Compound: 1	Antiproliferative activity against HCT116 cells Antiproliferative activity against HCT116 cells	[PMID: 16904890]
HCT-116	IC₅₀	0.013 μM Compound: 1	Concentration required to inhibit the HCT116 cell growth by 50%. Concentration required to inhibit the HCT116 cell growth by 50%.	[PMID: 11831887]
HCT-116	IC₅₀	0.043 μM Compound: 1, TSA	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	[PMID: 21073160]
HCT-116	IC₅₀	0.8 μM Compound: TSA	Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay	[PMID: 20452226]
HCT-116	IC₅₀	0.9 μM Compound: TSA	Inhibitory concentration against colon HCT116 cell line Inhibitory concentration against colon HCT116 cell line	[PMID: 12593661]
HCT-116	IC₅₀	13 nM Compound: Trichostatin A	Inhibitory activity against HCT116 human colon cell growth Inhibitory activity against HCT116 human colon cell growth	[PMID: 14521422]
HCT-116	IC₅₀	< 0.05 μM Compound: TSA	Inhibitory concentration required to reduce HCT 116 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce HCT 116 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
HEK293	IC₅₀	0.16 μM Compound: 5	Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay	[PMID: 25556102]
HEK293	IC₅₀	34 nM Compound: 1	Inhibition of human recombinant HDAC4 expressed in 293 cells Inhibition of human recombinant HDAC4 expressed in 293 cells	[PMID: 17929798]
HEK293	IC₅₀	81 nM Compound: 1	Inhibition of mouse recombinant HDAC6 expressed in 293 cells Inhibition of mouse recombinant HDAC6 expressed in 293 cells	[PMID: 17929798]
HL-60	GI₅₀	0.59 μM Compound: TRICHOSTATIN A	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	[PMID: 29454918]
HL-60	IC₅₀	0.03 μM Compound: Trichostatin A	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
HL-60	IC₅₀	0.08 μM Compound: TSA	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HMEC	IC₅₀	1.6 μM Compound: TSA	Inhibitory concentration required to reduce normal human epithelial cell line (HMEC), growth by 50% in MTT assay Inhibitory concentration required to reduce normal human epithelial cell line (HMEC), growth by 50% in MTT assay	[PMID: 12061890]
HMEC	IC₅₀	32 μM Compound: TSA	Inhibitory concentration against normal epithelial HMEC cell line Inhibitory concentration against normal epithelial HMEC cell line	[PMID: 12593661]
HT-1080	IC₅₀	0.08 μM Compound: TSA	Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
HT-29	GI₅₀	34.1 nM Compound: TSA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 30004697]
HT-29	IC₅₀	3.8 nM Compound: TSA	Antiproliferative activity against human HT-29 cells in presence of isoCA-4 after 72 hrs by MTS assay relative to control Antiproliferative activity against human HT-29 cells in presence of isoCA-4 after 72 hrs by MTS assay relative to control	[PMID: 30004697]
HT-29	IC₅₀	55 nM Compound: TSA	Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of HOSCN-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by one stage clotting assay Inhibition of HOSCN-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	30 nM Compound: TSA, trichostatin A	Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay	[PMID: 17675290]
HeLa	EC₅₀	0.0052 μM Compound: TSA	Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA	[PMID: 26611919]
HeLa	IC₅₀	0.0011 μM Compound: TSA	Inhibition of HDAC2 in human HeLa cell nuclear extracts in presence of dithiothreitol by HDAC fluorescent assay Inhibition of HDAC2 in human HeLa cell nuclear extracts in presence of dithiothreitol by HDAC fluorescent assay	[PMID: 22465091]
HeLa	IC₅₀	0.0075 μM Compound: Trichostatin A	Inhibition of HDAC in human HeLa cell extract after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell extract after 15 mins by fluorescence assay	[PMID: 25455492]
HeLa	IC₅₀	0.02 μM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract assessed as inhibition of histone H4 deacetylation after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract assessed as inhibition of histone H4 deacetylation after 15 mins by fluorescence assay	[PMID: 20381359]
HeLa	IC₅₀	0.09 μM Compound: TSA	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 27427973]
HeLa	IC₅₀	0.1 μM Compound: Trichostatin A	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
HeLa	IC₅₀	0.11 μM Compound: TSA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HeLa	IC₅₀	0.3 μM Compound: TSA	Inhibition of HDAC from human HeLa cells Inhibition of HDAC from human HeLa cells	[PMID: 18247554]
HeLa	IC₅₀	0.3 μM Compound: Trichostatin A	Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay	[PMID: 19457659]
HeLa	IC₅₀	0.85 μM Compound: 5	Cytotoxicity against human HeLa cells after 96 hrs by MTT assay Cytotoxicity against human HeLa cells after 96 hrs by MTT assay	[PMID: 25556102]
HeLa	IC₅₀	1.42 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay	[PMID: 26588603]
HeLa	IC₅₀	12 nM Compound: TSA	Inhibition of HDAC isolated from human HeLa cells by fluorimetric assay Inhibition of HDAC isolated from human HeLa cells by fluorimetric assay	10.1039/C4MD00211C
HeLa	IC₅₀	28.9 nM Compound: TSA	Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay	[PMID: 20167479]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cell cytosolic extract after 30 mins by fluorimetric assay Inhibition of HDAC in human HeLa cell cytosolic extract after 30 mins by fluorimetric assay	[PMID: 19705846]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay	[PMID: 19705846]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay	[PMID: 21621883]
HeLa	IC₅₀	39 nM Compound: TSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30245394]
HeLa	IC₅₀	41 nM Compound: TSA	Inhibition of Histone deacetylase in HeLa cell nuclear extracts by fluorescence-based assay Inhibition of Histone deacetylase in HeLa cell nuclear extracts by fluorescence-based assay	[PMID: 17419603]
HeLa	IC₅₀	5 nM Compound: TSA	Inhibition of human HDAC in HeLa cells by flour de lys assay Inhibition of human HDAC in HeLa cells by flour de lys assay	[PMID: 18397827]
HeLa	IC₅₀	5 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay	[PMID: 19914074]
HeLa	IC₅₀	5 nM Compound: Trichostatin A	Inhibition of histone deacetylase (HDAC) activity in HeLa cell nuclear extract Inhibition of histone deacetylase (HDAC) activity in HeLa cell nuclear extract	[PMID: 15109636]
HeLa	IC₅₀	54.5 nM Compound: 15	Inhibitory concentration against human histone deacetylase (HDAC) from HeLa cells with substrate 5a Inhibitory concentration against human histone deacetylase (HDAC) from HeLa cells with substrate 5a	[PMID: 15456267]
HepG2	EC₅₀	0.38 μM Compound: 5	Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay	[PMID: 25556102]
HepG2	IC₅₀	0.38 μM Compound: 4; TSA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability Cytotoxicity against human HepG2 cells assessed as reduction in cell viability	[PMID: 32005414]
HepG2	IC₅₀	0.96 μM Compound: 5	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 25556102]
Huh-7	CC₅₀	1.587 μM Compound: GNF-Pf-1011	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Huh-7	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
Huh-7	IC₅₀	0.09 μM Compound: Trichostatin A	Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
Huh-7	IC₅₀	0.1 μM Compound: TSA	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
Jurkat	IC₅₀	3.3 nM Compound: TSA	Tested for inhibitory concentration required to inhibit 50% of histone deacetylase (HDAC) from human T cell leukemia Jurkat cell Tested for inhibitory concentration required to inhibit 50% of histone deacetylase (HDAC) from human T cell leukemia Jurkat cell	[PMID: 11992774]
K-562R	GI₅₀	88 nM Compound: TSA	Antiproliferative activity against human K562R cells after 72 hrs by MTS assay Antiproliferative activity against human K562R cells after 72 hrs by MTS assay	[PMID: 30004697]
K562	GI₅₀	262 nM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 30004697]
K562	IC₅₀	0.0046 μM Compound: trichostatin	Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells. Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells.	[PMID: 10425110]
K562	IC₅₀	0.12 μM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
K562	IC₅₀	0.16 μM Compound: Trichostatin A	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
K562	IC₅₀	0.41 μM Compound: TSA	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
K562	IC₅₀	260 nM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human K562 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
K562	IC₅₀	560 nM Compound: TSA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 30245394]
K562	IC₅₀	90 nM Compound: TSA	Antiproliferative activity against imatinib-resistant human K562 cells over expressing MDR1 after 72 hrs by CellTiter Glo assay Antiproliferative activity against imatinib-resistant human K562 cells over expressing MDR1 after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
L02	IC₅₀	0.21 μM Compound: 5	Cytotoxicity against human LO2 cells after 96 hrs by MTT assay Cytotoxicity against human LO2 cells after 96 hrs by MTT assay	[PMID: 25556102]
MCF7	GI₅₀	45 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 30004697]
MCF7	IC₅₀	0.02 μM Compound: 1a	Cytotoxicity of compound against normal human breast MCF-7 cell line Cytotoxicity of compound against normal human breast MCF-7 cell line	[PMID: 15163181]
MCF7	IC₅₀	0.06 μM Compound: TSA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
MCF7	IC₅₀	0.06 μM Compound: Trichostatin A	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
MCF7	IC₅₀	0.07 μM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MCF7	IC₅₀	0.1 μM Compound: TSA	Inhibitory concentration required to reduce MCF-7 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce MCF-7 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
MCF7	IC₅₀	0.3 μM Compound: 4; TSA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability Cytotoxicity against human MCF7 cells assessed as reduction in cell viability	[PMID: 32005414]
MCF7	IC₅₀	1.7 μM Compound: TSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22465091]
MCF7	IC₅₀	10 μM Compound: TSA	Inhibitory concentration against breast MCF-7 cell line Inhibitory concentration against breast MCF-7 cell line	[PMID: 12593661]
MCF7	IC₅₀	141 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30245394]
MCF7	IC₅₀	20 nM Compound: TSA	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 30245394]
MCF7	IC₅₀	27.7 nM Compound: 8; TSA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay	[PMID: 34826681]
MCF7	IC₅₀	54 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MDA-MB-231	IC₅₀	0.09 μM Compound: TSA	Inhibitory concentration required to reduce MDAmb 231 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce MDAmb 231 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
MDA-MB-231	IC₅₀	3.5 μM Compound: TSA	Inhibitory concentration against breast MDA-MB-231 cell line Inhibitory concentration against breast MDA-MB-231 cell line	[PMID: 12593661]
MDA-MB-231	IC₅₀	91 nM Compound: TSA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MDA-MB-435	GI₅₀	1.78 μM Compound: TRICHOSTATIN A	Antiproliferative activity against human MDA-MB-435 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells after 24 hrs by MTT assay	[PMID: 29454918]
MDCK	IC₅₀	0.008 μM Compound: Trichostatin A	Antiviral activity against Influenza A virus A/Hong Kong/8/68 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by CCK8 assay Antiviral activity against Influenza A virus A/Hong Kong/8/68 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by CCK8 assay	10.1039/C3MD00371J
MIA PaCa-2	GI₅₀	200 nM Compound: TSA	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTS assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 30004697]
MIA PaCa-2	IC₅₀	0.9 μM Compound: 4; TSA	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability	[PMID: 32005414]
MIA PaCa-2	IC₅₀	200 nM Compound: TSA	Antiproliferative activity against human MIA PaCa-2 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MIA PaCa-2 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MKN-45	IC₅₀	0.1 μM Compound: TSA	Antiproliferative activity against human MKN45 cells Antiproliferative activity against human MKN45 cells	[PMID: 18247554]
MKN-45	IC₅₀	0.1 μM Compound: TSA (1)	Compound was tested for antiproliferative activity against human MKN45 cancer cell lines Compound was tested for antiproliferative activity against human MKN45 cancer cell lines	[PMID: 14667227]
MKN-45	IC₅₀	20 nM Compound: TSA	Antiproliferative activity against human MKN45 cells Antiproliferative activity against human MKN45 cells	[PMID: 30245394]
MM96L	IC₅₀	0.03 μM Compound: 1a	Cytotoxicity against human melanoma MM96L cell line Cytotoxicity against human melanoma MM96L cell line	[PMID: 15163181]
MM96L	IC₅₀	0.03 μM Compound: 1a	Cytotoxicity against human melanoma MM96L cell line Cytotoxicity against human melanoma MM96L cell line	[PMID: 15163181]
MM96L	IC₅₀	0.03 μM Compound: TSA	Inhibition of human MM96L cells Inhibition of human MM96L cells	[PMID: 18247554]
MOLT-4	IC₅₀	0.02 μM Compound: TSA	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MOLT-4	IC₅₀	0.03 μM Compound: TSA	Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
MOLT-4	IC₅₀	0.03 μM Compound: Trichostatin A	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
MV4-11	EC₅₀	15.3 μM Compound: Trichostatin A	Antiproliferative activity against human MV4-11 cells assessed as cell viability by measuring amount of ATP after 72 hrs incubation by CellTiteer-Glo Cell viability assay Antiproliferative activity against human MV4-11 cells assessed as cell viability by measuring amount of ATP after 72 hrs incubation by CellTiteer-Glo Cell viability assay	[PMID: 39067437]
NCI-H1299	IC₅₀	0.1 μM Compound: 1	Antiproliferative activity against H1299 cells Antiproliferative activity against H1299 cells	[PMID: 16904890]
NCI-H1299	IC₅₀	100 nM Compound: Trichostatin A	Inhibitory activity against H1299 human lung carcinoma cell growth Inhibitory activity against H1299 human lung carcinoma cell growth	[PMID: 14521422]
NCI-H1975	IC₅₀	0.09 μM Compound: Trichostatin A	Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
NCI-H1975	IC₅₀	0.21 μM Compound: TSA	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
NCI-H446	IC₅₀	0.08 μM Compound: TSA	Inhibitory concentration required to reduce H446 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce H446 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
NCI-H446	IC₅₀	1.5 μM Compound: TSA	Inhibitory concentration against lung H446 cell line Inhibitory concentration against lung H446 cell line	[PMID: 12593661]
NCI-H460	IC₅₀	0.1 μM Compound: 1, TSA	Growth inhibition of human H460 cells after 48 hrs by SRB assay Growth inhibition of human H460 cells after 48 hrs by SRB assay	[PMID: 21073160]
NCI-H661	IC₅₀	0.085 μM Compound: 1 (TSA)	Antiproliferative activity against H661 cells after 48 hrs Antiproliferative activity against H661 cells after 48 hrs	[PMID: 17897824]
NCI-H661	IC₅₀	0.085 μM Compound: 7, TSA	Antiproliferative activity against H661 cells after 48 hrs by XTT assay Antiproliferative activity against H661 cells after 48 hrs by XTT assay	[PMID: 17624773]
NCI-H661	IC₅₀	0.1 μM Compound: 1, TSA	Antiproliferative activity against human NCI-H661 cells after 48 hrs by XTT assay Antiproliferative activity against human NCI-H661 cells after 48 hrs by XTT assay	[PMID: 19385600]
NCI-H661	IC₅₀	< 0.3 μM Compound: 1	Antiproliferative activity against H661 cells Antiproliferative activity against H661 cells	[PMID: 16904890]
NCI-N87	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
NCI-N87	IC₅₀	58 nM Compound: TSA	Antiproliferative activity against human NCI-N87 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
NFF	IC₅₀	0.2 μM Compound: 1a	Cytotoxicity of compound against human normal neonatal foreskin fibroblasts (NFF) cell line Cytotoxicity of compound against human normal neonatal foreskin fibroblasts (NFF) cell line	[PMID: 15163181]
NFF	IC₅₀	0.2 μM Compound: 1a	Cytotoxicity of compound against normal human normal neonatal foreskin fibroblasts (NFF) Cytotoxicity of compound against normal human normal neonatal foreskin fibroblasts (NFF)	[PMID: 15163181]
NFF	IC₅₀	200 nM Compound: TSA	Cytotoxicity against human NFF cells Cytotoxicity against human NFF cells	[PMID: 30245402]
NFF	IC₅₀	6.7 μM Compound: TSA	Selectivity index, ratio of IC50 for human MM96L cells to IC50 for human NFF cells Selectivity index, ratio of IC50 for human MM96L cells to IC50 for human NFF cells	[PMID: 18247554]
NIH3T3	IC₅₀	0.006 μM Compound: Trichostatin A	Inhibition of HDAC1 in human NIH3T3 cells by radiometric histone deacetylation assay Inhibition of HDAC1 in human NIH3T3 cells by radiometric histone deacetylation assay	[PMID: 19457659]
NIH3T3	IC₅₀	21 nM Compound: 1	Inhibition of human recombinant HDAC1 expressed in NIH3T3 cells Inhibition of human recombinant HDAC1 expressed in NIH3T3 cells	[PMID: 17929798]
PANC-1	IC₅₀	0.1 μM Compound: TSA	Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
PC-3	GI₅₀	387 nM Compound: TSA	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 30004697]
S2	IC₅₀	0.6 nM Compound: 3, TSA	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	[PMID: 19317450]
SGC-7901	IC₅₀	0.03 μM Compound: TSA	Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
SH-SY5Y	IC₅₀	18.8 nM Compound: Trichostatin A	Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	7.8 nM Compound: Trichostatin A	Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	9.1 nM Compound: Trichostatin A	Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SK-BR-3	IC₅₀	0.02 μM Compound: TSA	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 18247554]
SK-BR-3	IC₅₀	0.02 μM Compound: TSA (1)	Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines	[PMID: 14667227]
SK-BR-3	IC₅₀	0.05 μM Compound: TSA	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
SK-BR-3	IC₅₀	20 nM Compound: TSA	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 30245394]
SK-MEL-28	IC₅₀	0.28 μM Compound: 1a	Cytotoxicity of compound against normal human melanoma SK-MEL-28 cell line Cytotoxicity of compound against normal human melanoma SK-MEL-28 cell line	[PMID: 15163181]
SK-OV-3	IC₅₀	100 nM Compound: TSA	Antiproliferative activity against human SK-OV-3 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SK-OV-3 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
SNU-16	IC₅₀	53 nM Compound: TSA	Inhibition of HDAC from human SNU16 cells Inhibition of HDAC from human SNU16 cells	[PMID: 18247554]
SNU-16	IC₅₀	53.29 nM Compound: TSA (1)	Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells	[PMID: 14667227]
SQ20B	IC₅₀	0.2 μM Compound: TSA	Inhibition of human SQ20B cells Inhibition of human SQ20B cells	[PMID: 18247554]
SW-620	IC₅₀	2.454 μM Compound: 11; TSA	Antiproliferative activity against human SW620 cells Antiproliferative activity against human SW620 cells	[PMID: 38142509]
SW48	IC₅₀	0.1 μM Compound: TSA	Inhibitory concentration required to reduce SW48 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce SW48 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
SW48	IC₅₀	5 μM Compound: TSA	Inhibitory concentration against colon SW48 cell line Inhibitory concentration against colon SW48 cell line	[PMID: 12593661]
Sf21	IC₅₀	0.032 μM Compound: TSA	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay	[PMID: 30448419]
Sf21	IC₅₀	1.58 x 10^-8 M Compound: Trichostatin A	Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorimetric assay Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorimetric assay	[PMID: 31838329]
Sf21	IC₅₀	17.9 nM Compound: Trichostatin A	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	[PMID: 31924504]
Sf21	IC₅₀	25 nM Compound: TSA	Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay	[PMID: 32212730]
Sf21	IC₅₀	3.95 x 10^-8 M Compound: Trichostatin A	Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry assay Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry assay	[PMID: 31838329]
Sf21	IC₅₀	6.574 x 10^-9 M Compound: TSA	Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	[PMID: 27060764]
Sf21	IC₅₀	9 nM Compound: TSA	Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay	[PMID: 32212730]
Sf9	IC₅₀	0.00068 μM Compound: TSA	Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.00161 μM Compound: TSA	Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.002 μM Compound: TSA	Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by substrate addition and further incubated for 2 hrs by fluorescence assay Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by substrate addition and further incubated for 2 hrs by fluorescence assay	[PMID: 31414801]
Sf9	IC₅₀	0.00274 μM Compound: TSA	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.009 μM Compound: TSA	Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by substrate addition and further incubated for 2 hrs by fluorescence assay Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by substrate addition and further incubated for 2 hrs by fluorescence assay	[PMID: 31414801]
Sf9	IC₅₀	0.482 μM Compound: TSA	Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.776 μM Compound: TSA	Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.9 nM Compound: TSA	Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	1.2 nM Compound: TSA	Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	1.716 x 10^-9 M Compound: TSA	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 27060764]
Sf9	IC₅₀	129 nM Compound: TSA	Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	15.7 nM Compound: Trichostatin A	Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
Sf9	IC₅₀	17.3 nM Compound: TSA	Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	9 nM Compound: TSA	Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	960 nM Compound: 1, TSA	Inhibition of N terminal hexahistidine-tagged human HDAC8 expressed in Sf9 cells after 1 hr by fluorescence assay Inhibition of N terminal hexahistidine-tagged human HDAC8 expressed in Sf9 cells after 1 hr by fluorescence assay	[PMID: 21723733]
Sf9	IC₅₀	> 1 μM Compound: TSA	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1 μM Compound: TSA	Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
T-24	EC₅₀	0.01 μM Compound: TSA	Induction of alpha tubulin acetylation in human T24 cells Induction of alpha tubulin acetylation in human T24 cells	[PMID: 19111466]
T-24	EC₅₀	0.01 μM Compound: TSA	Induction of histone H3 acetylation in human T24 cells Induction of histone H3 acetylation in human T24 cells	[PMID: 19111466]
T-24	EC₅₀	1 μM Compound: 2 - TSA	Inhibition of acetylation of histone-4 in human T-24 cancer cells Inhibition of acetylation of histone-4 in human T-24 cancer cells	[PMID: 14613312]
T-24	EC₅₀	4 μM Compound: 2 - TSA	Inhibition of acetylation of histone-4 in human T-24 cancer cells Inhibition of acetylation of histone-4 in human T-24 cancer cells	[PMID: 14613312]
T-24	IC₅₀	0.15 μM Compound: TSA	Inhibitory concentration required to reduce T24 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce T24 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
T-24	IC₅₀	4 μM Compound: TSA	Inhibitory concentration against bladder T24 cell line Inhibitory concentration against bladder T24 cell line	[PMID: 12593661]
T47D	IC₅₀	26.4 nM Compound: 8; TSA	Antiproliferative activity against human T47D cells assessed as cell growth inhibition by burton method Antiproliferative activity against human T47D cells assessed as cell growth inhibition by burton method	[PMID: 34826681]
U-251	IC₅₀	611.2 nM Compound: 2	Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	[PMID: 17643112]
U-87MG ATCC	GI₅₀	1038 nM Compound: TSA	Antiproliferative activity against human U87 cells after 72 hrs by MTS assay Antiproliferative activity against human U87 cells after 72 hrs by MTS assay	[PMID: 30004697]
U-937	IC₅₀	0.04 μM Compound: TSA	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
U-937	IC₅₀	0.05 μM Compound: Trichostatin A	Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
U-937	IC₅₀	0.1 μM Compound: TSA	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
U2OS	IC₅₀	14.93 μM Compound: 5	Cytotoxicity against human U2OS cells after 96 hrs by MTT assay Cytotoxicity against human U2OS cells after 96 hrs by MTT assay	[PMID: 25556102]
Vero	IC₅₀	0.6 μM Compound: Trichostatin A	Antiviral activity against EV71 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 to 96 hrs by CCK8 assay Antiviral activity against EV71 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 to 96 hrs by CCK8 assay	10.1039/C3MD00371J
Vero	IC₅₀	41.2 ng/mL Compound: TSA	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	49.5 ng/mL Compound: TSA	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	95 ng/mL Compound: TSA	Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay	[PMID: 19914074]
WiDr	IC₅₀	577.6 nM Compound: 2	Inhibition of SAP130 mediated cell growth in human WiDr cells Inhibition of SAP130 mediated cell growth in human WiDr cells	[PMID: 17643112]

In Vitro

Trichostatin A is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC. Trichostatin A (TSA) inhibits proliferation of eight breast carcinoma cell lines with mean±SD IC₅₀ of 124.4±120.4 nM (range, 26.4-308.1 nM). HDAC inhibitory activity of Trichostatin A is similar in all cell lines with mean IC₅₀ of 2.4±0.5 nM (range, 1.5-2.9 nM)^[1]. Trichostatin A (330 nM) increases Gαs protein expression in human myometrial cells, but does not increase Gαs mRNA levels^[2]. Trichostatin A (20-75 nM) induces minimal cytotoxicity to adipose-derived stem cells (ADSCs), and enhances the osteogenic differentiation capacity of ADSCs^[3]. In addition, Trichostatin A (0, 10, 100, 500 nM) dose-dependently decreases HDAC class I/II activity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Trichostatin A (500 μg/kg, s.c.) pronounces antitumor activity without causing any measurable toxicity in doses of up to 5 mg/kg by s.c. injection, in randomized controlled efficacy studies using the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

302.37

Formula

C₁₇H₂₂N₂O₃

CAS No.

58880-19-6

Appearance

Solid

Color

White to light yellow

SMILES

CN(C1=CC=C(C=C1)C([C@@H](/C=C(/C=C/C(NO)=O)C)C)=O)C

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (165.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Methanol : 2 mg/mL (6.61 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3072 mL	16.5360 mL	33.0721 mL
5 mM	0.6614 mL	3.3072 mL	6.6144 mL
10 mM	0.3307 mL	1.6536 mL	3.3072 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.27 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.5 mg/mL (8.27 mM); Suspended solution; Need ultrasonic
Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.91%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (243 KB) HNMR (263 KB) LCMS (265 KB) OR (170 KB) Elemental Analysis Report (101 KB)

Handling Instructions (2659 KB)

References

[1]. Vigushin DM et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001 Apr;7(4):971-6. [Content Brief]

[2]. Karolczak-Bayatti M, et al. Expression of the GTP-Binding Protein Gαs in Human Myometrial Cells is Regulated by Ubiquitination and Protein Degradation: Involvement of Proteasomal Inhibition by Trichostatin A.,Reprod Sci. 2012 Aug 8. [Content Brief]

[3]. Hu X, et al. Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.,Stem Cells Dev. 2012 Aug 8. [Content Brief]

[4]. Azechi T, et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J Atheroscler Thromb. 2013;20(6):538-47. [Content Brief]

Cell Assay ^[3]	Cells are cultured in a 96-well plate at 1×10³ cells per well with 100 μL complete DMEM in the presence or absence of a HDAC inhibitor Trichostatin A for 72 h. Cytotoxicity is measured by performing WST-8 assay using a CCK-8 cell proliferation kit. The 450 nm absorbance is measured with a microplate reader. All experiments are carried out in triplicate and 3 independent experiments are performed^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Rats^[1] Twelve rats are randomized to receive 500 μg/kg Trichostatin A in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection twice weekly for 4 weeks. In subsequent studies, 30 rats are randomized to receive Trichostatin A 500 μg/kg in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection daily for 4 weeks. Weekly tumor measurements, estimated tumor volumes, and body mass are recorded for each animal. Animals are sacrificed at the end of the 4-week study period; palpable tumors are resected and immediately snap-frozen in liquid nitrogen. Animals with tumors <2 cm in diameter or ulcerating tumors are withdrawn from study^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Vigushin DM et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001 Apr;7(4):971-6. [Content Brief] [2]. Karolczak-Bayatti M, et al. Expression of the GTP-Binding Protein Gαs in Human Myometrial Cells is Regulated by Ubiquitination and Protein Degradation: Involvement of Proteasomal Inhibition by Trichostatin A.,Reprod Sci. 2012 Aug 8. [Content Brief] [3]. Hu X, et al. Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.,Stem Cells Dev. 2012 Aug 8. [Content Brief] [4]. Azechi T, et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J Atheroscler Thromb. 2013;20(6):538-47. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Methanol / DMSO	1 mM	3.3072 mL	16.5360 mL	33.0721 mL	82.6802 mL
Methanol / DMSO	5 mM	0.6614 mL	3.3072 mL	6.6144 mL	16.5360 mL
DMSO	10 mM	0.3307 mL	1.6536 mL	3.3072 mL	8.2680 mL
	15 mM	0.2205 mL	1.1024 mL	2.2048 mL	5.5120 mL
	20 mM	0.1654 mL	0.8268 mL	1.6536 mL	4.1340 mL
	25 mM	0.1323 mL	0.6614 mL	1.3229 mL	3.3072 mL
	30 mM	0.1102 mL	0.5512 mL	1.1024 mL	2.7560 mL
	40 mM	0.0827 mL	0.4134 mL	0.8268 mL	2.0670 mL
	50 mM	0.0661 mL	0.3307 mL	0.6614 mL	1.6536 mL
	60 mM	0.0551 mL	0.2756 mL	0.5512 mL	1.3780 mL
	80 mM	0.0413 mL	0.2067 mL	0.4134 mL	1.0335 mL
	100 mM	0.0331 mL	0.1654 mL	0.3307 mL	0.8268 mL

Trichostatin A Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Trichostatin A58880-19-6TSAOrganoidHDACHistone deacetylasesInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Trichostatin A (Synonyms: TSA)

Customer Review

Other Forms of Trichostatin A:

Trichostatin A Related Antibodies

176 Publications Citing Use of MCE Trichostatin A

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HDAC Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Trichostatin A Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Trichostatin A Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report